Who We Are
Our Doctrine
We are Committed to the Philosophy of Excellence.
(Commitment: A pledge to do a specific act or a thing; the state of being bound emotionally or intellectually to a course of action. Philosophy: A system of motivating concepts or principles; the system of values by which one lives. Excellence: The state, quality of condition of excelling; superiority)
We are dedicated to meet our Client's needs.
(Client: One who gives us a chance to provide him our services)
We work as a Team with our business partners in a spirit of trust and cooperation.
(Teamwork: Cooperative effort by group members to achieve a common goal. Business partners: Those with whom we do business - our customers and suppliers)
We believe in open Communication.
(Communication: The exchange of thoughts, messages or information)
We live and work Ethically.
(Ethics: The accepted principles of right and wrong that govern the conduct of an individual in relationship with others)
Each individual in our organization is Important and Responsible.
(Importance: Having great value, significance or consequence Responsible: Dependable, accountable, in-charge)
We focus on Accountability for every assignment.
(Accountable: Answerable; capable of being explained)
Our History
Established as a consulting services company in 1983 – Apothecaries became the first Indian contract clinical research organization in 1993.
Since then we’ve been involved in clinical trials across Phase I to IV, for therapeutic areas such as Infectious diseases (bacterial, viral and others), Oncology, Dermatology (and VD), Respiratory System (including Asthma, COPD), Cardiology (including CHF, MI, Dyslipidemia), Psychiatry, Genito-Urinary System, Endocrinology (including diabetes), Nervous System (including CNS, PNS, Stroke), Pediatrics, Gastro-Intestinal System, Gynaecology, Pain Management, Organ Transplantation, Vaccines, Orthopedics, Dentistry, Haematology, Surgery, and Medical Devices.
Apothecaries has also emerged as a major Indian regulatory consultancy organization for global blue-chip as well as for emerging pharma companies based at US, EU, Japan, Australia and India.